Celcuity Inc. Common Stock
CELCCelcuity Inc. (CELC) is a biotechnology company focused on developing personalized cancer therapies through its innovative molecular and cellular analysis platform. The company utilizes its proprietary diagnostic technology to identify specific patient subgroups, enabling targeted treatments and improving clinical outcomes. Celcuity aims to translate complex biological data into actionable insights for better cancer treatment strategies.
Company News
The article highlights three small-cap stocks that have shown impressive gains in 2025, including a biotech company, a fintech platform, and an online consignment store, each with unique market potential and growth trajectories.
Apis Capital Advisors invested $38.3 million in Celcuity, acquiring 776,000 shares during Q3 2025, making it their largest holding. Celcuity, a clinical-stage biotech firm, has seen its stock surge 669% in a year following positive phase 3 results for its cancer drug gedatolisib.
Celcuity announced promising Phase 3 trial results for gedatolisib, a multi-target PAM inhibitor for advanced breast cancer, demonstrating significant improvements in progression-free survival and response rates compared to standard treatment.
Celcuity reported promising Phase 1 clinical trial results for gedatolisib combined with darolutamide in metastatic castration-resistant prostate cancer, showing a 67% six-month progression-free survival rate and generally well-tolerated treatment.
Celcuity announced full enrollment of the PIK3CA mutant cohort in its Phase 3 VIKTORIA-1 clinical trial, with expected topline data in late Q1 or Q2 2026. Preliminary Phase 1b data showed promising median progression-free survival of 14.6 months for patients with PIK3CA-mutated advanced breast cancer.
